Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
50 EUR | +0.30% | +2.35% | -3.47% |
May. 01 | DRÄGERWERK AG & CO KGAA : China weighs on Q1 24 growth | |
Apr. 29 | DRAEGERWERK : Hauck & Aufhauser reiterates its Buy rating | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Its low valuation, with P/E ratio at 9.04 and 8.63 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company shows low valuation levels, with an enterprise value at 0.31 times its sales.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company has a low valuation given the cash flows generated by its activity.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company sustains low margins.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-3.47% | 949M | B+ | ||
+7.84% | 218B | B | ||
+7.35% | 184B | B- | ||
+13.04% | 135B | B- | ||
+26.03% | 107B | A- | ||
-1.33% | 62.38B | A- | ||
+11.80% | 51.37B | B+ | ||
+4.81% | 50.9B | B+ | ||
+0.30% | 40.87B | A | ||
+2.78% | 36.28B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DRW3 Stock
- Ratings Drägerwerk AG & Co. KGaA